Found that:
Liver-protective action of silymarin therapy in chronic alcoholic liver diseases
Orvosi Hetilap 130 (1989), 2723-2727
J.Fehér, G. Deàk, G.Müzes, I.Làng, V.Niederland, K.Nékám, K.Mihàly
Semmelweiss University, II. Belklinika, Egyetern, Hungary
Abstract: The effects of silymarin (Legalon® *) therapy on liver function tests, serum procollagen III peptide levels and liver histology were studied in 36 patients with chronic alcoholic liver disease in a six months double blind clinical trial. During silymarin treatment serum bilirubin, aspartate aminotransferase and alanine aminotransferase values have been normalized, while gamma-glutamyl transferase activity and procollagen III peptide level decreased. The changes were significant, and there was a significant difference between post-treatment values of the two groups, as well. In the placebo group only gamma-glutamyl transferase values decreased significantly but to a lesser extent than that in the silymarin group. The histological alterations showed an improvement in the silymarin group, while remained unchanged in the placebo group. These results indicate that silymarin exerts hepatoprotective activity and is able to improve liver functions in alcoholic patients.
And this:
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
Journal of Hepatology 9 (1989), 105 - 113
P. Ferenci(1), B. Dragosics(1), H. Dittrich(2), H. Frank(3), L. Benda(4), H. Lochs(1), S. Mervn(1), W. Base(1) and B. Schneider(5)
(1)1st Department of Gastroenterology and Hepatology, University of Vienna, Austria
(2)Ambulatorium Süd der Wiener Gebietskrankenkasse, Vienna, Austria
(3)Department of Internal Medicine, Sophienspital, Vienna, Austria
(4)Department of Internal Medicine, Krankenhaus Floridsdorf, Vienna, Austria
(5)Institute of Biometry, Medical University Hannover, Germany
Abstract: Silymarin, the active principle of the milk thistle Silybum marianum, protects experimental animals against various hepatotoxic substances. To determine the effect of silymarin on the outcome of patients with cirrhosis, a double blind, prospective, randomized study was performed in 170 patients with cirrhosis. 87 patients (alcoholic 46, non-alcoholic 41; 61 male, 26 female; Child A 47, B 37, C 3; mean age 57) received 140 mg silymarin three times daily. 84 patients (alcoholic 45, non-alcoholic 38; 62 male, 21 female; Child A 42, B 32, C 9; mean age 58) received a placebo. Non-compliant patients and patients who failed to come to a control were considered as "drop outs" and were withdrawn from the study. All patients received the same treatment until the last patient entered had finished 2 years of treatment. The mean observation period was 41 months. There were 10 drop-outs in the placebo group and 14 in the treatment group. In the placebo group, 37 (+ 2 drop outs) patients had died, and in 31 of these, death was related to liver disease. In the treatment group, 24 (+ 4 drop outs) had died, and in 18 of these, death was related to liver disease. The 4-year survival rate was 58 +/- 9% (S.E.) in silymarin-treated patients and 39 +/- 9% in the placebo group (p=0.036). Analysis of subgroups indicated that treatment was effective in patients with alcoholic cirrhosis (p=0.01) and in patients initially rated "Child A" (p=0.03). No side effects of drug treatment was observed. The results of this study suggest that mortality of patients with cirrhosis was reduced by treatment with silymarin. However, as this effect was more pronounced in alcoholic cirrhosis, the interrelation of patterns of alcohol consumption and of drug treatment affecting survival must be addressed by future studies.
Also see attachment!
~abuleh